🇺🇸 FDA
Pipeline program

MEROPENEM AND VABORBACTAM , LINEZOLID , TEDIZOLID , SULFAMETHOXAZOLE AND TRIMETHOPRIM , -, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , -, DAPTOMYCIN , -, COLISTIN , -, METRONIDAZOLE , AMIKACIN , IMIPENEM, CILASTATIN AND RELEBACTAM

Approved small_molecule active

Quick answer

MEROPENEM AND VABORBACTAM , LINEZOLID , TEDIZOLID , SULFAMETHOXAZOLE AND TRIMETHOPRIM , -, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , -, DAPTOMYCIN , -, COLISTIN , -, METRONIDAZOLE , AMIKACIN , IMIPENEM, CILASTATIN AND RELEBACTAM for Pyogenic liver abscess is a Approved program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Pyogenic liver abscess
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials